The landscape of GLP-1 receptor agonists is shifting, and not just for obesity or diabetes. A new trend is emerging—microdosing these powerful drugs. Patients and some physicians are exploring lower-than-recommended doses to manage weight, improve metabolic health, reduce inflammation, and lower costs. But is this approach safe and effective?
